Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Naloxone OTC Switch NDA Has US FDA Concerned Labeling Will Cause User Error, Delay Delivery

Feb 14 2023

• By Malcolm Spicer

• Source: Shutterstock

Related Content

US FDA Asks Sponsors Of Discontinued Naloxones To Consider Return To Market

Jul 09 2019

Self-Selection Studies Need Room To Evaluate Purchase Decisions – Expert

Sep 26 2011

Merck Silence On OTC <em>Singulair</em> Speaks Volumes On Switch Outlook

Dec 11 2015

Light Still On For Switches After Pfizer Pulls Plug On OTC <em>Lipitor</em>

Aug 03 2015

OTC Primatene Mist Returns: Market Future Bright After Cloudy NDA History

Nov 10 2018

Naloxone Model OTC Label Expected From US FDA As Part Of Opioids Strategy

Oct 23 2018

Additional Topics

International United States Advisory Committees Prescription To OTC Switch FDA Business Strategies Commercial Clinical Trials Companies Compliance Consumer Distribution Drug Approval Standards Ingredients Manufacturing OTC Drugs Policy Retail Regulation Research & Development Safety

More from Rx-to-OTC Switch

More from Health

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window